tbuckley/cabot-search huggingface dataset:
Cyclophosphamide-induced Myopia
Authors: José Alberto Arranz, Rafael Jiménez, Melchor Alvarez-Mon
Journal: Annals of Internal Medicine (1992)

Letters1 January 1992Cyclophosphamide-induced MyopiaJosé Alberto Arranz, MD, Rafael Jiménez, MD, Melchor Alvarez-Mon, MD, PhDJosé Alberto Arranz, MDSearch for more papers by this author, Rafael Jiménez, MDSearch for more papers by this author, Melchor Alvarez-Mon, MD, PhDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-116-1-92_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors: Cyclophosphamide is widely used in the treatment of cancer and autoimmune diseases (1-3). Several secondary effects have been described in patients treated with this drug, depending on the dose and mode of administration (1, 2). Although blurred vision has occasionally been associated with cyclophosphamide, the mechanism has not been explained (4). We describe a patient with recurrent transitory myopia induced by the intravenous bolus administration of cyclophosphamide bolus in a patient with systemic lupus erythematosus.A 15-year-old girl was diagnosed as having systemic lupus erythematosus with diffuse proliferative glomerulonephritis. Treatment was begun with daily steroids and monthly...References1. Colvin M. A review of the pharmacology and clinical use of cyclophosphamide. In: Pinedo HM, ed. Clinical Pharmacology of Antineoplastic Drugs. Amsterdam: Elsevier/North Holland; 1978:245-61. Google Scholar2. Kovarsky J. Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases. Seminars in Rheumatic Diseases. 1983;12:359-71. Google Scholar3. AustinKlippelBalow HJJ. Therapy of lupus nephritis. N Engl J Med. 1986;314:614-9. CrossrefMedlineGoogle Scholar4. KendeSirkinThomasFreeman GSPA. Blurring of vision. A previously undescribed complication of cyclophosphamide therapy. Cancer. 1979;44:69-71. CrossrefMedlineGoogle Scholar5. Grant W. Lens, iris and anterior chamber disturbances. In: Toxicology of the Eye. Volume II. Springfield, Illinois: Charles C. Thomas; 1986. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Universidad de Alcalá de Henares Madrid, Spain PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMyopia: Ocular and Systemic DiseaseOncolytic DrugsCyclophosphamideDrug-induced ocular side effectsMyopia: Ocular and Systemic DiseaseDRUGS USED IN CANCER CHEMOTHERAPYGLUCOCORTICOIDS AND DISEASE – MODIFYING ANTIRHEUMATIC DRUGSDrug-induced ocular side effectsCyclophosphamideDevelopment of ceramic breeder blankets in JapanShape distortions of meson resonances produced in hadron interactions atP T≧2 GeV/cCytostatics and immunosuppressive drugsCyclophosphamide 1 January 1992Volume 116, Issue 1Page: 92-93KeywordsAutoimmune diseasesCancer treatmentCyclophosphamideDrug administrationDrugsGlomerulonephritisLupus erythematosusSteroidsVision Issue Published: 1 January 1992 PDF downloadLoading ...
Effects of Intravenous Hydration and Pitressin on Renal Function in Subjects with Essential Hypertension
Authors: WILLIAM HOLLANDER
Journal: Circulation (1959)

Various abnormalities in metabolism of water and electrolytes have been noted in patients with arterial hypertension and have variously been considered as causes or results of the hypertension. In this paper new data on these relationships are presented by a study of the changes in renal function produced by intravenous hydration, Pitressin, and lowering of the blood pressure.
Radionuclide angiographic evaluation of right and left ventricular function during exercise after repair of transposition of the great arteries. Comparison with normal subjects and patients with congenitally corrected transposition.
Authors: M D Parrish, T P Graham, H W Bender, J P Jones, J Patton, C L Partain
Journal: Circulation (1983)

We assessed the incidence, clinical significance and etiology of ventricular dysfunction after intraatrial repair of d-transposition of the great arteries in 11 patients, mean age 9 +/- 3 years, who had had Mustard operations. We compared the results to 15 patients who were considered to have normal ventricular function, two patients who had Rastelli operations and five patients with congenitally corrected transposition. Gated equilibrium radionuclide angiography with supine exercise stress testing was used to assess these children. We found no significant difference between our patient groups in exercise capacity, heart rate, or blood pressure response to exercise. However, we found a high incidence of right ventricular dysfunction in the patient groups, manifested by an abnormal right ventricular ejection fraction response to dysfunction in the patient groups, manifested by an abnormal right ventricular ejection fraction response to exercise in six of 11 patients with a Mustard repair, both patients with a Rastelli repair and all five with congenitally corrected transposition. In addition, the left ventricular response to exercise was abnormal in 10 of 11 patients who had undergone a Mustard repair, both patients with a Rastelli repair, and two of five patients with congenitally corrected transposition. We conclude that biventricular dysfunction is frequently present after intraatrial repair of d-transposition of the great arteries. Despite this dysfunction, no significant decrease in exercise tolerance is found in childhood.
Endoscopic Sclerosis versus Cyanoacrylate Endoscopic Injection for the First Episode of Variceal Bleeding: A Prospective, Controlled, and Randomized Study in Child-Pugh Class C Patients
Authors: F. Maluf-Filho, P. Sakai, S. Ishioka, S. E. Matuguma
Journal: Endoscopy (2001)

Background and Study Aims: Despite the recognized efficacy of sclerotherapy and elastic band ligation in controlling variceal hemorrhage, the results of endoscopic treatment in Child-Pugh class C patients remain poor. The aim of this prospective, controlled, and randomized study was to compare conventional sclerotherapy with injection of the tissue adhesive N-butyl-2-cyanoacrylate in controlling the first episode of rupturing of esophageal varices.
The effect of multidrug-resistance 1 gene versus neotransduction on ex vivo and in vivo expansion of rhesus macaque hematopoietic repopulating cells
Authors: Stephanie E. Sellers, John F. Tisdale, Brian A. Agricola, Mark E. Metzger, Robert E. Donahue, Cynthia E. Dunbar, Brian P. Sorrentino
Journal: Blood (2001)
Ambient ozone modifies the effect of tumor necrosis factor G‐308A on bronchitic symptoms among children with asthma
Authors: Y.‐L. Lee, R. McConnell, K. Berhane, F. D. Gilliland
Journal: Allergy (2009)

Tumor necrosis factor (TNF)-alpha has a recognized role in respiratory pathophysiology. One genetic variant (G-308A) in the promoter region affecting the expression of this cytokine may contribute to airway inflammatory diseases, but the studies on bronchitic symptoms were still inconclusive. Because ozone produces oxidative stress, increased airway TNF, and inflammation, the associations of the TNF-308 polymorphism with bronchitic symptoms may vary by ambient ozone exposure.We studied associations of TNF-308 genotype with bronchitic symptoms among asthmatic children in Children's Health Study. The association of TNF G-308A polymorphism with bronchitic symptoms was investigated and we also determined whether the associations vary with ambient ozone exposure.Asthmatic children with TNF-308 GG genotype had a significantly reduced risk of bronchitic symptoms with low-ozone exposure (adjusted OR: 0.53; 95% CI: 0.31-0.91). The risk was not reduced in children living in high-ozone communities (adjusted OR: 1.42; 95% CI: 0.75-2.70). This difference in genotypic effects between low- and high-ozone environments was statistically significant among asthmatics (P for interaction = 0.01), but insignificant among nonasthmatic children.Our findings suggest a role of gene-environmental interactions on the occurrence of bronchitic symptoms among children with asthma.
Highly Sensitive Noninvasive Cardiac Transplant Rejection Monitoring Using Targeted Quantification of Donor-Specific Cell-Free Deoxyribonucleic Acid
Authors: Mats Hidestrand, Aoy Tomita-Mitchell, Pip M. Hidestrand, Arnold Oliphant, Mary Goetsch, Karl Stamm, Huan-Ling Liang, Chesney Castleberry, D. Woodrow Benson, Gail Stendahl, Pippa M. Simpson, Stuart Berger, James S. Tweddell, Steven Zangwill, Michael E. Mitchell
Journal: Journal of the American College of Cardiology (2013)
Temple of Learning or Tower of Babel?
Authors: Harold Stevens
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Challenges to implementing the national programme for information technology (NPfIT): a qualitative study
Authors: Jane Hendy, Barnaby C Reeves, Naomi Fulop, Andrew Hutchings, Cristina Masseria
Journal: BMJ (2005)

<h3>Abstract</h3> <b>Objectives</b> To describe the context for implementing the national programme for information technology (NPfIT) in England, actual and perceived barriers, and opportunities to facilitate implementation. <b>Design</b> Case studies and in depth interviews, with themes identified using a framework developed from grounded theory. <b>Setting</b> Four acute NHS trusts in England. <b>Participants</b> Senior trust managers and clinicians, including chief executives, directors of information technology, medical directors, and directors of nursing. <b>Results</b> The trusts varied in their circumstances, which may affect their ability to implement the NPfIT. The process of implementation has been suboptimal, leading to reports of low morale by the NHS staff responsible for implementation. The overall timetable is unrealistic, and trusts are uncertain about their implementation schedules. Short term benefits alone are unlikely to persuade NHS staff to adopt the national programme enthusiastically, and some may experience a loss of electronic functionality in the short term. <b>Conclusions:</b> The sociocultural challenges to implementing the NPfIT are as daunting as the technical and logistical ones. Senior NHS staff feel these have been neglected. We recommend that national programme managers prioritise strategies to improve communication with, and to gain the cooperation of, front line staff.
Direct stimulation of bone resorption by thyroid hormones.
Authors: G R Mundy, J L Shapiro, J G Bandelin, E M Canalis, L G Raisz
Journal: Journal of Clinical Investigation (1976)

Although hypercalcemia, osteoporosis, and increased bone turnover are associated with thyrotoxicosis, no direct effects of thyroid hormones on bone metabolism have been reported previously in organ culture. We have now demonstrated that prolonged treatment with thyroxine (T4) or triiodothyronine (T3) can directly increase bone resorption in cultured fetal rat long bones as measured by the release of previously incorporated 45Ca. T4 and T3 at 1 muM to 10 nM increased 45Ca release by 10-60% of total bone 45Ca during 5 days of culture. The medium contained 4 mg/ml of bovine serum albumin to which 90% of T4 and T3 were bound, so that free concentrations were less than 0.1 muM. The response to T4 and T3 was inhibited by cortisol (1 muM) and calcitonin (100 mU/ml). Indomethacin did not inhibit T4 response suggesting that T4 stimulation of bone resorption was not mediated by increased prostaglandin synthesis by the cultured bone. Matrix resorption was demonstrated by a decrease in extracted dry weight and hydroxyproline concentration of treated bones and by histologic examination which also showed increased osteoclast activity. The effects of thyroid hormones were not only slower than those of other potent stimulators of osteoclastic bone resorption (parathyroid hormone, vitamin D metabolites, osteoclast activating factor, and prostaglandins), but the maximum response was not as great. We conclude that T4 and T3 can directly stimulate bone resorption in vitro at concentrations approaching those which occur in thyrotoxicosis. This effect may explain the disturbances of calcium metabolism seen in hyperthyroidism.
Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events
Authors: Caitriona Ryan, Craig L. Leonardi, James G. Krueger, Alexa B. Kimball, Bruce E. Strober, Kenneth B. Gordon, Richard G. Langley, James A. de Lemos, Yahya Daoud, Derek Blankenship, Salahuddin Kazi, Daniel H. Kaplan, Vincent E. Friedewald, Alan Menter
Journal: JAMA (2011)

Ustekinumab and briakinumab, monoclonal antibodies to the shared p40 subunit of interleukin (IL)-12 and IL-23, have shown efficacy in treating chronic plaque psoriasis (CPP). Preliminary reports of major adverse cardiovascular events (MACEs) in psoriasis patients receiving anti-IL-12/23 agents have prompted concern.To evaluate a possible association between biologic therapies for CPP and MACEs via meta-analysis.Randomized controlled trials (RCTs) of anti-IL-12/23 (ustekinumab and briakinumab) agents and anti-tumor necrosis factor α (TNF-α) agents (adalimumab, etanercept, and infliximab) used in treating CPP were reviewed using the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and Ovid MEDLINE from database inception to May 2011. The results of registered nonpublished completed studies were procured through abstract publications or poster presentations.Randomized, placebo-controlled, double-blind, monotherapy studies (with safety outcome data for MACE) of IL-12/23 antibodies and anti-TNF-α agents in adults. Studies of psoriatic arthritis were excluded.Two investigators independently searched data while 6 investigators reviewed the abstracted data.A total of 22 RCTs comprising 10 183 patients met the predefined inclusion criteria. The primary outcome measure was MACE, a composite end point of myocardial infarction, cerebrovascular accident, or cardiovascular death during the placebo-controlled phase of treatment in patients receiving at least 1 dose of study agent or placebo. Absolute risk differences were used as an effect measure. There was no evidence of statistical heterogeneity across the studies using the I(2) statistic (I(2) = 0), allowing for combination of trial results using the Mantel-Haenszel fixed-effects method. During the placebo-controlled phases of the anti-IL-12/23 studies, 10 of 3179 patients receiving anti-IL-12/23 therapies experienced MACEs compared with zero events in 1474 patients receiving placebo (Mantel-Haenszel risk difference, 0.012 events/person-year; 95% confidence interval [CI], -0.001 to 0.026; P =.12). In the anti-TNF-α trials, only 1 of 3858 patients receiving anti-TNF-α agents experienced a MACE compared with 1 of 1812 patients receiving placebo (Mantel-Haenszel risk difference, -0.0005 events/person-year; 95% CI, -0.010 to 0.009; P = .94).Compared with placebo, there was no significant difference in the rate of MACEs observed in patients receiving anti-IL-12/IL-23 antibodies or anti-TNF-α treatments. This study may have been underpowered to identify a significant difference.
Diversity in Organization and the Origin of Gene Orders in the Mitochondrial DNA Molecules of the Genus Saccharomyces
Authors: Casper Groth, Randi Føns Petersen, Jure Piškur
Journal: Molecular Biology and Evolution (2000)

Sequencing of the Saccharomyces cerevisiae nuclear and mitochondrial genomes provided a new background for studies on the evolution of the genomes. In this study, mitochondrial genomes of a number of Saccharomyces yeasts were mapped by restriction enzyme analysis, the orders of the genes were determined, and two of the genes were sequenced. The genome organization, i.e., the size, presence of intergenic sequences, and gene order, as well as polymorphism within the coding regions, indicate that Saccharomyces mtDNA molecules are dynamic structures and have undergone numerous changes during their evolution. Since the separation and sexual isolation of different yeast lineages, the coding parts have been accumulating point mutations, presumably in a linear manner with the passage of time. However, the accumulation of other changes may not have been a simple function of time. Larger mtDNA molecules belonging to Saccharomyces sensu stricto yeasts have acquired extensive intergenic sequences, including guanosine-cytosine-rich clusters, and apparently have rearranged the gene order at higher rates than smaller mtDNAs belonging to the Saccharomyces sensu lato yeasts. While within the sensu stricto group transposition has been a predominant mechanism for the creation of novel gene orders, the sensu lato yeasts could have used both transposition- and inversion-based mechanisms.
South African doctors charged with involvement in organ trade
Authors: Pat Sidley
Journal: BMJ (2004)

The South African medical establishment has found itself at the heart of an international scandal involving the sale and transplantation of kidneys on three continents.

The donors were mostly poor Brazilians willing to sell a kidney for up to $10 000 (£5400; €8000) each. The recipients were Israelis who paid up to 10 times that amount for a kidney.

A senior nephrologist, Dr Jeff Kallmeyer, is on trial in Durban facing …
WDR19 Expression is Increased in Prostate Cancer Compared with Normal Cells, but Low-Intensity Expression in Cancers is Associated with Shorter Time to Biochemical Failures and Local Recurrence
Authors: Biaoyang Lin, Angelita G. Utleg, Karsten Gravdal, James T. White, Ole J. Halvorsen, Wei Lu, Lawrence D. True, Robert Vessella, Paul H. Lange, Peter S. Nelson, Leroy Hood, Karl-Henning Kalland, Lars A. Akslen
Journal: Clinical Cancer Research (2008)

Abstract Purpose: Prostate cancer is the third leading cause of cancer death in the United States, following lung and colorectal cancer. We previously identified WDR19 as a prostate-specific, androgen-regulated gene. Here, we evaluate its utility as a prostate cancer tissue marker for diagnosis and prognostic evaluation. Experimental Design: Real-time quantitative PCR was done on a panel of prostate tissue isolated by laser capture microdissection. After generating antibodies against WDR19, tissue microarrays (TMA) were employed to compare WDR19 expression between normal, benign prostatic hyperplasia, and prostate cancer tissue. Results: Using microarrays and real-time quantitative PCR, we showed that WDR19 mRNA expression was increased in cancer. We further showed that WDR19 protein is localized to cytoplasmic subcellular granules and is expressed exclusively in prostate epithelia. Large-scale immunohistochemical staining using TMAs reveals a significant percentage of increase in intensely staining tissue cores in cancer tissue when compared with normal or benign prostatic hyperplastic tissue. Based on the analysis of a separate TMA for which clinical follow-up information was available, low-intensity WDR19 staining was significantly associated with decreased time to biochemical failure (P = 0.006) and with decreased time to locoregional recurrence (P = 0.050). Conclusions: WDR19 should be added to the list of prostate cancer tissue markers. The continued expansion of a multiple-marker panel will conceivably increase the sensitivity and specificity of prostate cancer diagnosis and prognosis.
Re: Beat Roth, Frédéric D. Birkhäuser, Pascal Zehnder, et al. Readaptation of the Peritoneum Following Extended Pelvic Lymphadenectomy and Cystectomy Has a Significant Beneficial Impact on Early Postoperative Recovery and Complications: Results of a Prospective Randomized Trial. Eur Urol 2011;59:204–10
Authors: Yiping Zhu, Dingwei Ye
Journal: European Urology (2010)
FRI0538 Juvenile Idiopathic Arthritis: from Childhood to Adult Life: Table 1
Authors: J.A. Melo-Gomes, S. Fernandes, S. Melo-Gomes, F. Martins
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Juvenile Idiopathic Arthritis (JIA) is not a single disease but a term used to classify a group of inflammatory rheumatic diseases (Arthritis) of unknown etiology (Idiopathic) diagnosed before the patient reaches 16 years of age (Juvenile). Many of these conditions remain active until adulthood and when patients are followed by adult Rheumatologists they may be followed continually by the same physician. Some investigators have published papers regarding the transition of these conditions into adulthood. The aim of this is to analyze the characteristics of 196 JIA patients, currently in their adulthood, that have been followed, in most of their disease, by the same Rheumatologist with a follow-up time superior to 30 years in some cases. <h3>Objectives</h3> To evaluate a cohort of patients with diagnosis of JIA from inicial presentation until adulthood and to determine the evolution regarding definitive diagnosis. <h3>Methods</h3> This study includes 196 patients currently in their adult age from a sample of 359 JIA patients, continuously followed by the first author in Child, Adolescent and Young Adult Rheumatology Consultation at IPR and Private Practice. All these patients are registered in REUMA.PT, the National Registry for rheumatic diseases of the Sociedade Portuguesa de Reumatologia. <h3>Results</h3> The group included 121 female and 75 male patients, with a mean age of 30.2±11.0 years, having mean disease duration of 21.0±11.2 years. The presentation forms and definitive diagnosis are listed below. Fifty nine of these patients are in complete and prolonged off therapy remission and 3 of them have secondary amyloidosis, as a complication of JIA. In regards to the treatment, 103 patients were treated with methotrexate, 39 are or were previously treated with biological agents, and 28 had been subjected to intra-articular injections (triamcinolone hexacetonide). Other aspects concerning therapy, morbidity and mortality were also analyzed. All of these patients are registered in SPR database (REUMA.PT). <h3>Conclusions</h3> It9s clear that JIA are a group of severe joint diseases that affects children and may continue to affect these patients throughout their adult life. A significative group of these patients can be classified as Juvenile Spondylarthritis (73/196 =37%) This analysis shows that JIAs are not a benign and self-limiting disease group, being essential to ensure the proper continuity of rheumatologic care for these patients in adulthood. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5472